Overview

GlaxoSmithKline, commonly known as GSK, is a British multinational biopharmaceutical company headquartered in London. The modern company was created in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, bringing together businesses whose histories reach back through Glaxo, Burroughs Wellcome, SmithKline French and Beecham. Although the group inherited a broad healthcare portfolio, its current identity is centered on research-based medicines and vaccines rather than mass-market consumer products. GSK’s principal areas include infectious diseases, HIV, respiratory medicine, immunology, oncology and vaccines. The company develops and commercializes prescription medicines for hospitals, specialist physicians and primary-care providers, while also supplying vaccines through public-health systems, national immunization programs and private healthcare channels. Important products and franchises have included the respiratory medicines Advair, Trelegy Ellipta and Anoro Ellipta; HIV medicines developed through the ViiV Healthcare joint venture, including Triumeq, Dovato and long-acting treatments such as Cabenuva; the shingles vaccine Shingrix; the respiratory syncytial virus vaccine Arexvy; and specialty medicines including Benlysta for systemic lupus erythematosus and Ojjaara for myelofibrosis. The company’s strategy has changed materially since the early 2000s. GSK initially operated as a diversified healthcare group spanning prescription medicines, vaccines and consumer health brands. It later pursued portfolio reshaping through acquisitions, licensing agreements and business exchanges, including a major 2014 transaction with Novartis that expanded GSK’s vaccines business and created a majority-controlled consumer-health joint venture. GSK subsequently separated its consumer-health activities into Haleon, which became an independent public company in 2022. The separation left GSK focused on biopharmaceutical research, vaccines and specialty medicines. GSK’s commercial model combines internal research, external partnerships, acquisitions and global regulatory expertise. Its research priorities include immune-mediated disease, infectious disease, HIV, respiratory conditions and cancer. The company sells through healthcare systems, distributors, hospitals, pharmacies and specialist channels, with direct-to-consumer advertising used selectively where permitted. Its public positioning emphasizes science-led innovation, prevention and getting ahead of disease, while access, affordability, clinical evidence and responsible promotion remain important elements of its stakeholder communications. GSK is one of the world’s largest pharmaceutical and vaccine companies and is widely recognized for its scale in HIV treatment and prevention, shingles vaccination, respiratory care and infectious-disease research. At the same time, its history includes regulatory disputes, product-liability litigation and criticism of pharmaceutical marketing and pricing practices. These issues form part of the company’s public record but do not alter its current status as an active, publicly listed biopharmaceutical group.

History

GSK’s corporate ancestry combines several nineteenth- and twentieth-century healthcare businesses. Glaxo originated as a New Zealand-based food and pharmaceutical enterprise before developing a stronger pharmaceutical presence. Burroughs Wellcome, founded in the United Kingdom and later established in the United States, became known for research-based medicines. Glaxo and Burroughs Wellcome combined in the 1990s to form Glaxo Wellcome. SmithKline Beecham was itself the product of earlier combinations. SmithKline French and Beecham merged in 1989, creating a broad international healthcare company with prescription medicines, consumer products and research capabilities. The merger helped establish the corporate scale and geographic reach that later made a combination with Glaxo Wellcome strategically attractive. In 2000, Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline. The transaction created one of the world’s largest pharmaceutical companies, combining complementary research organizations, commercial infrastructures and product portfolios. Early GSK operated across prescription medicines, vaccines, consumer healthcare and other healthcare activities. Its major therapeutic interests included respiratory disease, anti-infective medicines, central nervous system treatments and vaccines. During the following decade, GSK expanded through acquisitions, licensing and research alliances while also facing pressure to improve productivity and concentrate resources on the most promising science. It acquired Corixa in 2005, adding immunotherapeutic capabilities and vaccine-related assets. The company also developed a substantial HIV franchise through ViiV Healthcare, a joint venture established with Pfizer in 2009 and later joined by Shionogi as a shareholder. ViiV became a dedicated HIV company serving treatment and prevention markets. A major strategic reconfiguration occurred in 2014, when GSK and Novartis agreed a three-part transaction. GSK acquired most of Novartis’s global vaccines business excluding influenza, while the companies combined their consumer-health operations in a joint venture controlled by GSK. GSK also transferred its oncology portfolio to Novartis. The transaction strengthened GSK’s vaccine position and altered the balance of its therapeutic portfolio. In the late 2010s, GSK continued to reshape its pipeline through acquisitions and divestments. The purchase of Tesaro in 2019 strengthened oncology capabilities, particularly in ovarian cancer. The company also continued to invest in respiratory medicine, HIV and vaccines while managing patent expiries and competition from generic and rival products. GSK’s largest structural change in the early 2020s was the separation of its consumer-health business. The business, which included brands such as Sensodyne, Voltaren, Panadol and consumer nutrition products, was combined into Haleon and spun out as an independent public company in 2022. GSK retained a biopharmaceutical identity and adopted a more focused strategy built around vaccines, infectious diseases, specialty medicines and selected growth areas in respiratory medicine and oncology. The post-separation company has pursued business development to reinforce its research pipeline. It acquired Bellus Health in 2023, adding the investigational cough treatment camlipixant, and agreed to acquire Aiolos Bio in 2024 for its respiratory pipeline. It also acquired Elsie Biotechnologies and IDRx in 2024, adding platform and oncology capabilities. These moves illustrate GSK’s continuing use of external innovation alongside internal discovery. Today, GSK operates as a publicly listed British biopharmaceutical company. Its best-known modern franchises include Shingrix, Arexvy, HIV treatments and prevention products, respiratory inhalers, Benlysta and oncology medicines. The company’s competitive position depends on vaccine manufacturing, specialty-care commercialization, long-term clinical development and the ability to convert research partnerships and acquisitions into approved medicines.

2024
Respiratory and platform acquisitions expanded
[12]Respiratory and platform acquisitions expandedcontractpharma.com
GSK announced acquisitions including Aiolos Bio, Elsie Biotechnologies and IDRx to strengthen respiratory, oligonucleotide and oncology capabilities.
2023
Bellus Health acquisition completed
[11]Tesaro acquiredgsk.com
GSK acquired Bellus Health to add camlipixant, an investigational treatment for refractory chronic cough.
2022
Haleon separation completed
[11]Tesaro acquiredgsk.com
GSK separated its consumer-health business into Haleon, leaving GSK focused on biopharmaceuticals.
2019
Tesaro acquired
[11]Tesaro acquiredgsk.com
GSK acquired Tesaro to strengthen its oncology portfolio and add expertise in cancer therapeutics.
2014
Three-part transaction with Novartis announced
[3]GSK and Novartis three-part transactiongsk.com
The agreement combined consumer-health businesses, transferred oncology assets and brought most of Novartis’s vaccines business to GSK.
2009
ViiV Healthcare established
[10]ViiV Healthcare establishedviivhealthcare.com
GSK and Pfizer created a dedicated HIV company, later joined by Shionogi, to develop and commercialize HIV medicines.
2005
Corixa acquisition announced
[9]Corixa acquisition announcedclearygottlieb.com
GSK agreed to acquire Corixa, a biotechnology company focused on immunotherapeutics, in a transaction reported at approximately $300 million.
2000
Glaxo Wellcome and SmithKline Beecham merge
[8]Glaxo Wellcome and SmithKline Beecham mergelink.springer.com
The merger created GlaxoSmithKline and combined the two companies’ research, manufacturing and international commercial operations.

Products and positioning

A science-led global biopharmaceutical company seeking to prevent disease and improve treatment through vaccines and specialty medicines.

Vaccine · 2017
Shingrix
A recombinant adjuvanted vaccine designed to prevent shingles and related complications caused by reactivation of varicella-zoster virus. Shingrix became one of GSK’s most important commercial vaccine franchises and is administered through public-health recommendations and private healthcare channels in multiple markets.
Vaccine · 2023
Arexvy
A respiratory syncytial virus vaccine developed for older adults. Its approval created a major new adult-vaccination franchise for GSK and extended the company’s focus on prevention of serious respiratory disease.
Respiratory medicine · 2017
Trelegy Ellipta
A once-daily inhaled triple therapy combining an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta2 agonist. It is used in maintenance treatment for chronic obstructive pulmonary disease and, in some markets, asthma.
Respiratory medicine · 1998
Advair
An inhaled combination of fluticasone propionate and salmeterol used in the maintenance treatment of asthma and chronic obstructive pulmonary disease. It was one of GSK’s historically important respiratory brands, although market exclusivity and competition have changed its commercial role over time.
Immunology medicine · 2011
Benlysta
A biologic treatment for systemic lupus erythematosus and related indications. Benlysta is marketed as a specialty medicine and has been supported by disease-awareness and patient-engagement activity aimed at improving recognition and treatment of lupus.
HIV medicine · 2019
Dovato
A two-drug HIV treatment combining dolutegravir and lamivudine. It is commercialized through ViiV Healthcare, the specialist HIV company created by GSK and Pfizer with later participation from Shionogi.
HIV medicine · 2021
Cabenuva
A long-acting injectable HIV treatment based on cabotegravir and rilpivirine. It is intended to reduce the frequency of daily oral dosing for appropriate patients and represents ViiV’s emphasis on long-acting HIV care.
Oncology medicine · 2023
Ojjaara
A targeted medicine for adults with myelofibrosis and associated anemia in approved indications. Its addition broadened GSK’s specialty-oncology presence beyond its established immunology and infectious-disease franchises.

Controversies

2021
Virginia woman files Zantac cancer lawsuit
In a lawsuit reported in August 2021, Deborah Haskins of Virginia sued the makers of Zantac, alleging that the drug caused her esophageal cancer and that its makers failed to warn consumers of the risks. The report notes that research had not explicitly linked Zantac to cancer. The account describes the filing and the plaintiff's allegations; it does not state a court outcome or any finding on the claims.
Source
2021
AstraZeneca sues Glaxo over Zejula licensing agreement
AstraZeneca filed a lawsuit in the U.K. against GlaxoSmithKline, alleging that a 2012 licensing agreement over the Zejula cancer drug was breached and seeking a greater share of sales.
Source
2020
Federal Court fines GSK and Novartis over Osteo Gel marketing
The Federal Court ordered GlaxoSmithKline to pay $1.5 million and Novartis to pay $3 million after the companies admitted breaching Australian consumer law through their marketing of Osteo Gel between 2012 and 2017. The court found that the marketing misled consumers about the product's effectiveness compared with Emulgel.
Source
2019
GSK announces global Zantac recall
GlaxoSmithKline announced a recall of prescription-only Zantac medicines in all markets as a precaution. The action followed a finding by the U.S. Food and Drug Administration of unacceptable levels of a probable cancer-causing impurity in the drug. GSK also stated that it was suspending the release, distribution and supply of all dose forms of Zantac products. The recall and suspension applied across all markets.
Source
2015
LeClair family files Zofran birth-defect lawsuit against GSK
Tomisha LeClair filed a lawsuit on behalf of her daughter against GlaxoSmithKline, alleging that GSK concealed birth-defect risks associated with Zofran and promoted it for morning sickness during pregnancy. The claims are allegations in the lawsuit.
Source
2014
China bribery investigation and settlement
Chinese authorities investigated allegations that GSK employees and intermediaries used improper payments and other inducements to influence medicine sales. The case led to criminal proceedings and a substantial fine against the company’s Chinese operating entity.
Source
2012
U.S. healthcare fraud settlement
GSK reached a major U.S. resolution concerning allegations related to the marketing and pricing of several medicines, including promotion beyond approved uses and reporting issues. The matter included civil and criminal components.
Source

Marketing campaigns

2021More Than Movement
Germany · Europe · Canada and Australia
For Voltaren, GSK partnered with System1 to test viewers’ emotional responses to advertising frame by frame. The resulting campaign sought to build a consistent story around the ways arthritis affects everyday life rather than relying only on scenes of post-treatment physical activity.
Outcome. The campaign was reported as receiving System1’s highest score for the advertiser at that time and was expanded across several international markets.
Source
2021Benlysta direct-to-consumer campaign
United States
GSK’s first reported direct-to-consumer campaign for Benlysta featured people living with lupus and used connected television services such as Hulu and Roku alongside digital and social communication for healthcare professionals.
Outcome. The campaign was intended to improve awareness of lupus and reinforce Benlysta’s position in the category.
Source
2020Ice Cold Faces
United Kingdom
GSK Consumer Healthcare and Gay Times Group adapted Sensodyne’s sensitive-teeth advertising with an LGBTQ+ cast and culturally specific creative. The work was designed to make inclusion part of the campaign’s representation rather than a short-term Pride-themed message.
Outcome. The campaign extended the existing Sensodyne creative platform into inclusive digital and social distribution.
Source
2012Olympic anti-doping tribute
United Kingdom and Olympic audiences
A TBWA-created campaign connected GSK with its role in steroid screening and anti-doping support at the 2012 Olympics. One film portrayed sprinter Marlon Devonish in an intense stadium setting and framed crowd energy as the athlete’s only permitted stimulant.
Outcome. The campaign served as a high-profile corporate reputation and Olympic association effort rather than a direct product advertisement.
Source

Brand decisions

2024
Aiolos Bio acquisitionM&A
Background
GSK wanted to expand its respiratory pipeline with an investigational long-acting therapy for asthma and related diseases.
Action taken
GSK agreed to acquire Aiolos Bio for an upfront payment and potential regulatory milestone payments, subject to transaction terms and completion conditions.
Aftermath
The deal added a respiratory development program and strengthened GSK’s external-innovation strategy.
Consideration. Up to $1.4 billion (Announced January 2024)
Source
2022
Consumer-health demergerStrategy
Background
GSK determined that consumer health and research-based biopharmaceuticals required distinct strategic and capital-allocation priorities.
Action taken
The consumer-health operations were separated into Haleon, an independent publicly listed company, while GSK retained vaccines and prescription medicines.
Aftermath
GSK became a more focused biopharmaceutical company and Haleon became a separate consumer-health group.
Source
2014
Three-part Novartis transactionM&A
Background
GSK sought to strengthen vaccines and consumer health while reducing its exposure to oncology through a large inter-conditional transaction with Novartis.
Action taken
GSK acquired Novartis’s non-influenza vaccines business, transferred its oncology portfolio to Novartis and formed a consumer-health joint venture in which GSK held the majority stake.
Aftermath
The transaction materially reshaped GSK’s portfolio and established the consumer-health business that was later separated as Haleon.
Source

Recent events

2022-01-19
Altos Labs announces Hal Barron as incoming CEO and co-chair[22]Altos Labs宣布Hal Barron将出任首席执行官兼联席主席genengnews.com
Reported: 2022-01-19
Altos Labs announced that Hal Barron would become its CEO and co-chair; he was scheduled to step down from GSK effective August 1 to join Altos.
Unconfirmed
Watsons launches more than 1,600 Sustainable Choices products[23]屈臣氏推出逾1,600款“Sustainable Choices”产品sunstar.com.ph
Reported: 2021-10-25
Watsons launched more than 1,600 “Sustainable Choices” products in stores and online, in collaboration with global supplier partners.
2021-08-26
Virginia woman files Zantac cancer lawsuit[17]Virginia woman files Zantac cancer lawsuitnaturalnews.com
Deborah Haskins sued the makers of Zantac, alleging that the drug caused her esophageal cancer and that its makers failed to warn consumers of the risks. The article says research had not explicitly linked Zantac to cancer.
2021-07-30
FDA approves Nucala for chronic rhinosinusitis with nasal polyps[24]FDA批准Nucala用于治疗伴鼻息肉的慢性鼻窦炎healio.com
Reported: 2021-07-30
The FDA approved Nucala as an add-on maintenance treatment for adults with chronic rhinosinusitis with nasal polyps who have an insufficient response to nasal corticosteroids.
Unconfirmed
FDA approves Shingrix for immunocompromised adults[25]FDA 批准 Shingrix 用于免疫功能低下成人finanznachrichten.de
Reported: 2021-07-26
The US Food and Drug Administration approved Shingrix for prevention of shingles in adults aged 18 and older at increased risk due to immunodeficiency or immunosuppression caused by known disease or therapy, GlaxoSmithKline said.
2021-07-01
Evotec acquires GlaxoSmithKline’s Verona site[26]Evotec收购葛兰素史克维罗纳园区finanznachrichten.de
Reported: 2021-07-01
Evotec acquired the Verona site from GlaxoSmithKline. The site was to be named Campus Levi-Montalcini.
2021-06-07
AstraZeneca sues Glaxo over Zejula licensing agreement[18]AstraZeneca sues Glaxo over Zejula licensing agreementstatnews.com
Reported: 2021-06-07
AstraZeneca filed a lawsuit in the U.K. against GlaxoSmithKline, alleging that a 2012 licensing agreement over the Zejula cancer drug was breached and seeking a greater share of sales.
2020-12-17
FDA approves BENLYSTA for adult active lupus nephritis[27]FDA 批准 BENLYSTA 用于成人活动性狼疮性肾炎finanznachrichten.de
Reported: 2020-12-17
The US Food and Drug Administration approved GSK's BENLYSTA for adults with active lupus nephritis who are receiving standard therapy, extending the US indication to include lupus nephritis for intravenous and subcutaneous formulations.
2020-08-12
GSK pledges $10 million for Philadelphia STEM equity effort[28]GSK承诺为费城STEM公平项目提供1000万美元whyy.org
Reported: 2020-08-12
GSK pledged $10 million over the next decade to help Black, Latino, and female students in Philadelphia pursue STEM careers. The grant will be channeled through the Philadelphia STEM Equity Collective, a collaboration involving GSK and other organizations.
Unconfirmed
FDA approves Blenrep for relapsed/refractory multiple myeloma[29]FDA批准Blenrep治疗复发／难治型多发性骨髓瘤curetoday.com
Reported: 2020-08-06
The U.S. Food and Drug Administration approved Blenrep for certain patients with relapsed or refractory multiple myeloma who have received four prior therapies. The approval was granted under accelerated approval based on the DREAMM-2 study.

Showing the 10 most recent.